Welcome to HealthcareBanker.com

Thank you for visiting HealthcareBanker.com a news aggregator of middle-market mergers and acquisition activity in the healthcare industries. This site addresses investment banking topics dealing with M&A, Capital Raising, Borrowing/Lending and other Corporate Development and Finance activities within the Healthcare Services, Healthcare IT, Medical Device, and Life Science industries.

Tuesday, October 27, 2015

No Slowing in VC Funding for Digital Health

Venture capital funding for healthcare technology rebounds, investors log $1.6 billion in deals in Q3


Venture capital funding for digital health rebounded in the third quarter of 2015, up 32 percent quarter over quarter with $1.6 billion doled out across 148 deals, according to a new report from Mercom Capital Group. 

VC cash for health IT has hit $3.57 billion in 2015 so far. 

"VC funding into healthcare IT companies bounced back this quarter after a slow start this year," said Mercom Capital CEO Raj Prabhu, in a statement. 

Most of the growth came from funding for technologies aimed at the public. Companies focused on the provider side gathered $357 million in 42 deals (compared to $473 million in 41 deals in Q2 2015). Consumer-focused firms raked in $1.2 billion in 106 deals this quarter compared to ($727 million in 98 deals in Q2 2015).

Friday, October 16, 2015

Seed Funds Laging For New Med Tech

Med tech VC financing tops $800M, but funding for new companies remains scarce

(from fierce medical devices)

Med tech companies raised $821 million in venture capital money during the third quarter, the most since Q2 2011, according to the MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association based on data provided by Thomson Reuters. It is one of the most impressive numbers on record, barring unsustainable heights close to or beyond the $1 billion mark reached during the run-up to the financial crisis is in 2007 and 2008.

But former AdvaMed CEO Stephen Ubl was not wrong to bemoan the state of med tech VC during the association's annual med tech conference. It remains true that U.S. VCs have less preference for med tech (but not biotech) investing these days, especially in early-stage companies. Stringent public and private insurance company reimbursement is often blamed as the latest contributor to the malaise.

Tuesday, October 13, 2015

2015 Q3 Healthcare M&A Record Deals


Q3:15 Health Care M&A, By Sector

(from Levin & Associates)

Health care M&A in the third quarter was quite robust, with 385 transactions reported across 13 sectors. That’s a new record for any third quarter, by the way. We’ll have the full break-out in The Health Care M&A Report, Third Quarter 2015, due to be published by the end of this month. In the meantime, here’s how the sectors fared in Q3:15.

Wednesday, October 7, 2015

OfferBoard Raising Capital for Breakthrough Heart Disease Screening Device

Heart Test Laboratories, Inc. Engages OfferBoard Securities for Capital Raise to Bring Next Gen EKG to Market


OfferBoard Securities, LLC announces it has been retained by medical device company Heart Test Laboratories, Inc. to provide investment banking services and assist with raising capital to bring the next generation EKG device (MyoVista) to market.

Heart Test Labs mission is to provide accurate, affordable screening tools for the early detection of heart disease, and the MyoVista is the culmination of over 15 years of R&D and $15MM invested to date. OfferBoard Securities, a national investment bank and broker-dealer, will assist Heart Test Labs with raising $2 million in order to fund inventory, working capital and support selling the MyoVista by early 2016. 
“Heart disease is common and deadly but treatable if detected early. Unfortunately we still live in a world where most people find out about their condition through a heart attack or worse death” said Heart Test Labs Chairman Andrew Simpson. “While cardiologists have the tools for effective treatment of heart disease,” continued Simpson, “the big diagnostic gap is identifying at an early stage who should seek treatment. This is where the MyoVista comes into play.”